Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Repligen Corp. (RGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $174.20, with a market capitalisation of $9.48B and a P/E ratio of 237.39. Over the past 52 weeks, its price has ranged from $100.99 to $188.73. This page covers its latest market performance, valuation, price trends and company information.
$9.48B | |
$173.76 | |
$327.32 | |
$1.22 | |
$174.73 | |
4.01K | |
1.11M | |
237.39 | |
$188.73 | |
$100.99 | |
-- | |
-- |
Repligen Corp. (RGEN) is trading at $174.20 in pre-market trading as of 2026-09-16 08:15:00, down 0.30% ($0.53) from the previous close of $174.73
Pre-market trading shows how investors are pricing RGEN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Repligen Corp. (RGEN) moved from $167.60 to $174.20, representing a gain of 3.94% ($6.60).
The stock traded between $161.14 and $175.86 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 853.27 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.4%
RGEN is currently trading at $174.20, placing it 83.4% of the way from its 52-week low of $100.99 to its 52-week high of $188.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Repligen Corp. (RGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.